| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 03/19/2002 | CA2251453C 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones |
| 03/19/2002 | CA2032797C Antithrombotic compounds |
| 03/15/2002 | CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/14/2002 | WO2002020841A2 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| 03/14/2002 | WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | WO2002020762A2 Tnf receptor-like molecules and uses thereof |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020718A2 Osteoclast-associated receptor |
| 03/14/2002 | WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | WO2002020616A1 Hla-a2.1 binding peptides and their uses |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020519A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | WO2002020501A2 Polyarylcarboxamides useful as lipid lowering agents |
| 03/14/2002 | WO2002020497A1 Compounds having anti-hepatitis c virus effect |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | WO2002020483A1 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 03/14/2002 | WO2002020053A1 Hla binding peptides and their uses |
| 03/14/2002 | WO2002020049A2 Eiav chimeric vaccine and diagnostic |
| 03/14/2002 | WO2002020021A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| 03/14/2002 | WO2002020007A1 Cathartic composition |
| 03/14/2002 | WO2002020002A2 A method for treating allergies |
| 03/14/2002 | WO2002020001A2 Two-component anti-emetic composition comprising dexamethasone and metoclopramide |
| 03/14/2002 | WO2002019994A2 The treatment of inflammatory disorders |
| 03/14/2002 | WO2002019986A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 03/14/2002 | WO2002019978A2 Use of ectoine or ectoine derivatives for oral care |
| 03/14/2002 | WO2002019961A2 Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 03/14/2002 | WO2001079278A8 Lactobacillus johnsonii bacteriocin, active against helicobacter pylori |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001066543A3 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 03/14/2002 | WO2001066119A3 Pharmaceutical compositions including alginates |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001064671A3 Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001061007A3 Fibroblast growth factor-23 molecules and uses thereof |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001045715A3 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 03/14/2002 | WO2001045684A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001036684A3 Mammalian toxicological response markers |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000050048A9 Bone marrow transplantation for hepatic regeneration and repair |
| 03/14/2002 | US20020032332 Hypotensive agents, antiallergens, antiasthma, treating bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorder, gastrointestinal motility or cardiovascular disorders |
| 03/14/2002 | US20020032229 Novel compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 03/14/2002 | US20020032228 Inhibiting adenylate cyclase with a composition comprising an amount of a heterocycle-containing compound (e.g., imidazole, Celebrex or DuP-697) effective to inhibit the generation of cAMP from ATP |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032212 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases |
| 03/14/2002 | US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032202 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032194 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020031544 Antiinflammatory agents |
| 03/14/2002 | US20020031529 Neurotoxin therapy for diabetes |
| 03/14/2002 | US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent |
| 03/14/2002 | US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity |
| 03/14/2002 | DE10043227A1 Neuartiges entwicklungsbiologisches Gen Novel biological developmental gene |
| 03/14/2002 | DE10041217A1 Verwendung von Dihydroboswelliasäuren oder hydrierten Extrakten aus Boswellia zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten körperlichen oder seelischen Zuständen Use of Dihydroboswelliasäuren or hydrogenated extracts of Boswellia for prophylactic and / or therapeutic treatment of unwanted physical or mental conditions |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422506A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421502A1 A method for treating allergies |
| 03/14/2002 | CA2421448A1 Hla binding peptides and their uses |
| 03/14/2002 | CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2421155A1 Osteoclast-associated receptor |
| 03/14/2002 | CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | CA2420225A1 Hla-a2.1 binding peptides and their uses |
| 03/14/2002 | CA2419601A1 The treatment of inflammatory disorders |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/13/2002 | EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene |
| 03/13/2002 | EP1186607A1 Optically active pyrrolopyridazine compounds |
| 03/13/2002 | EP1186602A2 Omeprazole sodium salt and its use as anti-ulcer agent |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185618A1 A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use |
| 03/13/2002 | EP1185612A2 Bioreactor design and process for engineering tissue from cells |
| 03/13/2002 | EP1185547A2 Gene expression modulated in gastrointestinal inflammation |
| 03/13/2002 | EP1185542A2 Purine derivatives |
| 03/13/2002 | EP1185540A1 Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents |
| 03/13/2002 | EP1185530A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| 03/13/2002 | EP1185529A1 Pyrazolobenzodiazepines as cdk2 inhibitors |
| 03/13/2002 | EP1185528A1 Inhibitors of il-12 production |
| 03/13/2002 | EP1185524A2 3-heteroarylalkyl substituted gaba analogs |
| 03/13/2002 | EP1185521A1 Substituted 1-aza-2-imino-heterocycles and their use as activators of nicotinic acetylcholine receptors |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185303A1 Inhibition of gastric acid production and/or secretion |
| 03/13/2002 | EP1185296A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185292A2 Use of interleukin-11 to treat hemorrhagic shock |